NOVATO, Calif., Sept. 5, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jeff Ajer, the current Vice President, Commercial Operations, the Americas, will be promoted to Senior Vice President, Chief Commercial Officer. Mr. Ajer has more than 20 years of experience building industry-leading commercial organizations within rare disease and specialty medicine. He will lead the company's global marketing and sales organizations and report directly to BioMarin's CEO, Jean-Jacques Bienaimé.
In his most recent role, Mr. Ajer had P&L responsibility for commercial operations throughout the Americas, including markets critical for company growth, such as the U.S. and Brazil, and led product marketing, reimbursement and sales operations for BioMarin. Since joining as one of the first sales and marketing employees, Mr. Ajer has played a leadership role in establishing BioMarin's successful commercial infrastructure and global footprint, shaped the launches and growth strategies for Naglazyme and Kuvan and led commercial planning for late-stage pipeline programs, including GALNS. Mr. Ajer initially joined the company in 2005, as Vice President of Sales and Marketing Operations.
Immediately prior to BioMarin, Mr. Ajer served as Vice President, Global Transplant Operations at Genzyme Corporation. His experience prior to Genzyme includes roles in sales, marketing and operations at SangStat Medical Corporation and ICN Pharmaceuticals. Mr. Ajer received both a B.S. in chemistry and a M.B.A. from the University of California, Irvine.Stephen Aselage, Executive Vice President, Chief Business Officer, will be leaving the company to pursue other opportunities effective October 15, 2012. Mr. Aselage will receive a severance payment based on the terms of his employment agreement. "We wish to thank Steve for his work building BioMarin's highly successful global commercial organization," said Mr. Bienaimé. "We are confident Jeff will leverage his deep commercial experience in the rare disease space and long tenure as a senior leader in our commercial organization to strengthen our global marketing and sales as we enter a potentially transformative era for the company and patients around the world."
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts